SARS-CoV-2 Aptamers

SARS-CoV-2 aptamers are S-Protein specific and may be a specific therapeutic agent for COVID-19 therapy

Development of Therapeutic Neutralizing DNA Aptamers Against SARS-CoV-2

Aptamers are RNA or DNA oligonucleotides (or peptides) that, through their 3-dimensional structures, bind to specific target molecules with high affinity and specificity. Aptamers are generated fast and applied in the inhibition, characterization of proteins, and specific detection.

Our Aptamers are S-Protein Specific and may be a Specific Therapeutic Agent for COVID-19 therapy.

Our Aptamers not only neutralize the SAR-CoV-2 Wild Type strain, but also neutralize alternate strains of SAR-COV-2: Delta, Mu, Delta+, Omicron, etc.

Our Aptamers specifically block the uptake of Pseudo-SAR-CoV-2 VLP by lung cells in vivo mouse model.

AYA’s Aptamers: A Promising Therapy for SARS-CoV-2 Disease

The Aptamers discovered by Ayass BioScience, LLC are able to inhibit the binding of SARS-CoV-2 virus to its receptor, and can, by inhibiting viral uptake and subsequent replication, be used in targeted COVID-19 therapy applications.

Aptamers offer several advantages over protein antibodies in both their clinical applicability and their less challenging synthetic process.

  1. Our Aptamers can penetrate tissues faster and more efficiently due to their small size.
  2. Our Aptamers are non-immunogenic
  3. Our Aptamers are thermally stable.
  4. Our Aptamers can be rapidly synthesized in large quantities at a low production cost.
  5. Our Aptamers in pre-clinical mouse studies demonstrate:
  • Aptamers specifically neutralize SARS-CoV-2 VLP uptake by lung cells of hACE-2 transgenic mice in vivo.
  • No histopathologic abnormalities in lung, heart, brain, kidneys,liver, spleen, lymph nodes.
  • No immunotoxic response in lung
  • No loss of mice body weight.
  • Aptamers traced up to 48 hours in mice various tissues.